These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28212563)

  • 1. Progression of motor deficits in glioma-bearing mice: impact of CNF1 therapy at symptomatic stages.
    Vannini E; Maltese F; Olimpico F; Fabbri A; Costa M; Caleo M; Baroncelli L
    Oncotarget; 2017 Apr; 8(14):23539-23550. PubMed ID: 28212563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The bacterial protein toxin, cytotoxic necrotizing factor 1 (CNF1) provides long-term survival in a murine glioma model.
    Vannini E; Panighini A; Cerri C; Fabbri A; Lisi S; Pracucci E; Benedetto N; Vannozzi R; Fiorentini C; Caleo M; Costa M
    BMC Cancer; 2014 Jun; 14():449. PubMed ID: 24939046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CTX-CNF1 Recombinant Protein Selectively Targets Glioma Cells In Vivo.
    Vannini E; Mori E; Tantillo E; Schmidt G; Caleo M; Costa M
    Toxins (Basel); 2021 Mar; 13(3):. PubMed ID: 33800135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrophysiology of glioma: a Rho GTPase-activating protein reduces tumor growth and spares neuron structure and function.
    Vannini E; Olimpico F; Middei S; Ammassari-Teule M; de Graaf EL; McDonnell L; Schmidt G; Fabbri A; Fiorentini C; Baroncelli L; Costa M; Caleo M
    Neuro Oncol; 2016 Dec; 18(12):1634-1643. PubMed ID: 27298309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cnf1 Variants Endowed with the Ability to Cross the Blood-Brain Barrier: A New Potential Therapeutic Strategy for Glioblastoma.
    Colarusso A; Maroccia Z; Parrilli E; Germinario EAP; Fortuna A; Loizzo S; Ricceri L; Tutino ML; Fiorentini C; Fabbri A
    Toxins (Basel); 2020 May; 12(5):. PubMed ID: 32375387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of RhoGTPases improves the behavioral phenotype and reverses astrocytic deficits in a mouse model of Rett syndrome.
    De Filippis B; Fabbri A; Simone D; Canese R; Ricceri L; Malchiodi-Albedi F; Laviola G; Fiorentini C
    Neuropsychopharmacology; 2012 Apr; 37(5):1152-63. PubMed ID: 22157810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CNF1 Enhances Brain Energy Content and Counteracts Spontaneous Epileptiform Phenomena in Aged DBA/2J Mice.
    Travaglione S; Ballan G; Fortuna A; Ferri A; Guidotti M; Campana G; Fiorentini C; Loizzo S
    PLoS One; 2015; 10(10):e0140495. PubMed ID: 26457896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacterial Toxins and Targeted Brain Therapy: New Insights from Cytotoxic Necrotizing Factor 1 (CNF1).
    Tantillo E; Colistra A; Vannini E; Cerri C; Pancrazi L; Baroncelli L; Costa M; Caleo M
    Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29857515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Rac GTPase-activating bacterial protein toxin CNF1 induces analgesia up-regulating mu-opioid receptors.
    Pavone F; Luvisetto S; Marinelli S; Straface E; Fabbri A; Falzano L; Fiorentini C; Malorni W
    Pain; 2009 Sep; 145(1-2):219-29. PubMed ID: 19608345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model.
    Dai B; Qi N; Li J; Zhang G
    Biochem Biophys Res Commun; 2018 Jul; 501(4):871-876. PubMed ID: 29758196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
    Towner RA; Ihnat M; Saunders D; Bastian A; Smith N; Pavana RK; Gangjee A
    BMC Cancer; 2015 Jul; 15():522. PubMed ID: 26177924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A therapeutic cancer vaccine against GL261 murine glioma.
    Kindy MS; Yu J; Zhu H; Smith MT; Gattoni-Celli S
    J Transl Med; 2016 Jan; 14():1. PubMed ID: 26727970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic necrotizing factor type 1 delivered by outer membrane vesicles of uropathogenic Escherichia coli attenuates polymorphonuclear leukocyte antimicrobial activity and chemotaxis.
    Davis JM; Carvalho HM; Rasmussen SB; O'Brien AD
    Infect Immun; 2006 Aug; 74(8):4401-8. PubMed ID: 16861625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Rho GTPase activating CNF1 improves associative working memory for object-in-place.
    De Viti S; Martino A; Musilli M; Fiorentini C; Diana G
    Behav Brain Res; 2010 Sep; 212(1):78-83. PubMed ID: 20362628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Adult Drosophila Glioma Model for Studying Pathometabolic Pathways of Gliomagenesis.
    Chi KC; Tsai WC; Wu CL; Lin TY; Hueng DY
    Mol Neurobiol; 2019 Jun; 56(6):4589-4599. PubMed ID: 30357574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The bacterial protein CNF1 as a new strategy against Plasmodium falciparum cytoadherence.
    Messina V; Loizzo S; Travaglione S; Bertuccini L; Condello M; Superti F; Guidotti M; Alano P; Silvestrini F; Fiorentini C
    PLoS One; 2019; 14(3):e0213529. PubMed ID: 30845261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models.
    Ziegler J; Pody R; Coutinho de Souza P; Evans B; Saunders D; Smith N; Mallory S; Njoku C; Dong Y; Chen H; Dong J; Lerner M; Mian O; Tummala S; Battiste J; Fung KM; Wren JD; Towner RA
    Neuro Oncol; 2017 Feb; 19(2):175-185. PubMed ID: 27416955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy.
    Baker GJ; Yadav VN; Motsch S; Koschmann C; Calinescu AA; Mineharu Y; Camelo-Piragua SI; Orringer D; Bannykh S; Nichols WS; deCarvalho AC; Mikkelsen T; Castro MG; Lowenstein PR
    Neoplasia; 2014 Jul; 16(7):543-61. PubMed ID: 25117977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CNF1 improves astrocytic ability to support neuronal growth and differentiation in vitro.
    Malchiodi-Albedi F; Paradisi S; Di Nottia M; Simone D; Travaglione S; Falzano L; Guidotti M; Frank C; Cutarelli A; Fabbri A; Fiorentini C
    PLoS One; 2012; 7(4):e34115. PubMed ID: 22523545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversible senescence of human colon cancer cells after blockage of mitosis/cytokinesis caused by the CNF1 cyclomodulin from Escherichia coli.
    Zhang Z; Aung KM; Uhlin BE; Wai SN
    Sci Rep; 2018 Dec; 8(1):17780. PubMed ID: 30542142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.